Correction: HP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapy.

Correction: HP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapy.

[This corrects the article DOI: 10.1371/journal.pone.0121207.].

Bibliographic Details
Main Authors:	Young-Ho Lee, Xiyong Liu, Fuming Qiu, Timothy R O'Connor, Yun Yen, David K Ann
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2015-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4395453?pdf=render

Similar Items

HP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapy.
by: Young-Ho Lee, et al.
Published: (2015-01-01)

BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme
by: Mary-Ann Xavier, et al.
Published: (2021-08-01)

Advances in the use of PARP inhibitor therapy for breast cancer
by: Kelly E McCann, et al.
Published: (2018-08-01)

PARP inhibitors in treatment of early stage breast cancer
by: A. Tutt
Published: (2021-04-01)

PARP inhibitors are a new area in the treatment of breast cancer
by: V. P. Letyagin
Published: (2014-08-01)

PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
by: Anthony Gonçalves, et al.
Published: (2020-05-01)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
by: Luyao Wang, et al.
Published: (2017-10-01)

Revealing biomarkers associated with PARP inhibitors based on genetic interactions in cancer genome
by: Qi Dong, et al.
Published: (2021-01-01)

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
by: Ye Han, et al.
Published: (2020-11-01)

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
by: Man Yee Keung, et al.
Published: (2020-03-01)

Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer
by: Camille Franchet, et al.
Published: (2021-08-01)

Dual Inhibitors of PARPs and ROCKs
by: Albert A. Antolín, et al.
Published: (2018-10-01)

Advances and perspectives of PARP inhibitors
by: Ming Yi, et al.
Published: (2019-11-01)

Virtual screening for plant PARP inhibitors – what can be learned from human PARP inhibitors?
by: Heym Peter-Paul, et al.
Published: (2012-05-01)

Biomarkers of the Metabolic Syndrome and Breast Cancer Prognosis
by: Meng-Hua Tao, et al.
Published: (2010-04-01)

PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?
by: Wei Yen Chan, et al.
Published: (2021-09-01)

PARP1 inhibitors in breast cancer therapy. Mechanism of action and clinical use
by: D. S. Dolgasheva, et al.
Published: (2020-06-01)

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
by: Man Yee T. Keung, et al.
Published: (2019-03-01)

Is there an epigenetic component underlying the resistance of triple-negative breast cancers to PARP inhibitors?
by: Amanda eLovato, et al.
Published: (2012-12-01)

Serine-linked PARP1 auto-modification controls PARP inhibitor response
by: Evgeniia Prokhorova, et al.
Published: (2021-07-01)

In vivo visualization of PARP inhibitor pharmacodynamics
by: Elizabeth S. McDonald, et al.
Published: (2021-04-01)

PARP inhibitor combinations in prostate cancer
by: Carmel Pezaro
Published: (2020-03-01)

PARP Inhibitors in Prostate and Urothelial Cancers
by: Rohan Garje, et al.
Published: (2020-02-01)

An update on PARP inhibitors for the treatment of cancer
by: Benafif S, et al.
Published: (2015-02-01)

In vitro analysis of PARP inhibitor nanoformulations
by: Baldwin P, et al.
Published: (2018-03-01)

Resistance to PARP-inhibitors in Cancer Therapy
by: Alicia eMontoni, et al.
Published: (2013-02-01)

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
by: Zhaozhen Wu, et al.
Published: (2021-02-01)

LSD1 overexpression is associated with poor prognosis in basal-like breast cancer, and sensitivity to PARP inhibition.
by: Satoi Nagasawa, et al.
Published: (2015-01-01)

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.
by: Sonja J Gill, et al.
Published: (2015-01-01)

DNA damage sensitization of breast cancer cells with PARP10/ARTD10 inhibitor
by: Hukkanen, M. (Mikko)
Published: (2019)

The Inhibition and Treatment of Breast Cancer with Poly (ADP-ribose) Polymerase (PARP-1) Inhibitors
by: Joseph A. De Soto, Xianyan Wang, Yohei Tominaga, Rui-Hong Wang, Liu Cao, Wenhui Qiao, Cuiling Li, Xiaoling Xu, Amanda P. Skoumbourdis, Sheila A. Prindiville, Craig J. Thomas, Chu-Xia Deng
Published: (2006-01-01)

Differential regulation of breast cancer bone metastasis by PARP1 and PARP2
by: Hao Zuo, et al.
Published: (2020-03-01)

Breast cancer biomarkers: Prognosis and prediction
by: Nešković-Konstantinović Zora B., et al.
Published: (2002-01-01)

Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer
by: Dong Wang, et al.
Published: (2017-03-01)

The complete genome and methylome of Helicobacter pylori hpNEAfrica strain HP14039
by: Binit Lamichhane, et al.
Published: (2019-02-01)

The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency
by: Marco Gatti, et al.
Published: (2020-08-01)

Revealing the selective mechanisms of inhibitors to PARP-1 and PARP-2 via multiple computational methods
by: Hongye Hu, et al.
Published: (2020-05-01)

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
by: Hyoung Kim, et al.
Published: (2020-07-01)

Bioactivities of HP-β-CD/cinnamaldehyde complex
by: Wu,Chanying, et al.
Published: (2012)

PARP INHIBITORS IN OVARIAN CANCER: TOXICITY PROFILE
by: S. V. KHOKHLOVA, et al.
Published: (2017-06-01)

Cannot write session to /tmp/vufind_sessions/sess_vj7rpi4bc3plsva4fon8rua5fn